Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Aramark Reports Earnings Results for Fiscal 2026 (Business Wire) +++ ARAMARK Aktie -5,53%

VIVANI MEDICAL Aktie

 >VIVANI MEDICAL Aktienkurs 
0.895 EUR    -2.2%    (TradegateBSX)
Ask: 0.94 EUR / 3190 Stück
Bid: 0.9 EUR / 3354 Stück
Tagesumsatz: 73 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
VIVANI MED Aktie über LYNX handeln
>VIVANI MEDICAL Performance
1 Woche: -5,9%
1 Monat: -11,2%
3 Monate: -21,1%
6 Monate: -8,0%
1 Jahr: -21,1%
laufendes Jahr: -12,0%
>VIVANI MEDICAL Aktie
Name:  VIVANI MEDICAL
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US92854B1098 / A3DTRX
Symbol/ Ticker:  U5P (Frankfurt) / VANI (NASDAQ)
Kürzel:  FRA:U5P, ETR:U5P, U5P:GR, NASDAQ:VANI
Index:  -
Webseite:  https://vivani.com/
Profil:  Vivani Medical Inc. is a clinical-stage biopharmaceutical company focused on developing miniature, ultra long-acting subdermal drug implants using its proprietary NanoPortal technology. The company’s current work centers on implant-based therapies ..
>Volltext..
Marktkapitalisierung:  82.66 Mio. EUR
Unternehmenswert:  85.15 Mio. EUR
Umsatz:  -
EBITDA:  -24.98 Mio. EUR
Nettogewinn:  -24.53 Mio. EUR
Gewinn je Aktie:  -0.3 EUR
Schulden:  15.8 Mio. EUR
Liquide Mittel:  13.24 Mio. EUR
Operativer Cashflow:  -22.99 Mio. EUR
Bargeldquote:  2.22
Umsatzwachstum:  -
Gewinnwachstum:  -7.59%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  1 Insider kaufte innerhalb der letzten 30 Tage Aktien im Wert von 17.833 Euro.
Suchwörter:  VIVANI MEDICAL, VIVANI MED
Letzte Datenerhebung:  16.11.26
>VIVANI MED Kennzahlen
Aktien/ Unternehmen:
Aktien: 90.2 Mio. St.
Frei handelbar: 41.95%
Rückkaufquote: -41.25%
Mitarbeiter: 42
Umsatz/Mitarb.: -
Analysten:
Analystenrating: Strong buy
Kursziel: 255.97%
Bewertung:
KGV: -
KGV lG: -
KUV: -
KBV: 7.74
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: -
Gewinnmarge: -
Operative Marge: -
Managementeffizenz:
Gesamtkaprendite: -89.58%
Eigenkaprendite: -372.18%
>VIVANI MED Peer Group
Gesundheit, Stoffwechselerkrankungen (Diabetes/ Adipositas), Medizinprodukte & -technik/ Implantate/ Wundpflege
 
16.11.26 - 12:30
Vivani Medical raises $5.1M through private placement with board members (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
16.11.26 - 11:32
Vivani Medical Announces Private Placement Equity Financing (GlobeNewswire EN)
 
Vivani Medical announces $5.1M private placement equity financing...
14.11.26 - 05:01
Insiderhandel: Chief Business Officer kauft Aktien von Vivani Medical im Wert von 19645 USD (Insiderkauf)
 
Dwyer, Donald - Vorstand - Tag der Transaktion: 2026-11-12...
12.11.26 - 14:03
Vivani Medical Announces Positive Top-Line Results from SLIM-1™, a First in Human Phase 1 Trial of NPM-139 (semaglutide implant) and Wegovy (weekly semaglutide injections) in Obese and Overweight Subjects (GlobeNewswire EN)
 
Vivani Phase 1 study reports no nausea or vomiting and comparable weight loss to Wegovy controls with once- or twice-yearly GLP-1 implant....
11.11.26 - 22:15
Vivani Medical GAAP EPS of -$0.08 beats by $0.01 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
11.11.26 - 22:06
Vivani Medical Reports Third Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire EN)
 
Top-line results for SLIM-1™, the first-in-human Phase 1 trial of NPM-139, Vivani's miniature, ultra-long-acting semaglutide implant under development for chronic weight management, are anticipated for announcement later this week...
12.10.26 - 13:01
Vivani Medical Announces Participation in Upcoming Investor Conferences (GlobeNewswire EN)
 
Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra-long-acting drug implants utilizing its proprietary NanoPortal™ technology, today announced its participation in two investor conferences taking place this week in New York, New York:...
11.09.26 - 13:54
Vivani Medical auf H.C. Wainwright Konferenz: Entwicklung von Adipositas-Implantat gewinnt an Fahrt (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
13.08.26 - 22:27
Vivani Medical GAAP EPS of -$0.07 beats by $0.01 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
06.08.26 - 14:06
Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management (GlobeNewswire EN)
 
Dosing of the first participant commenced ahead of schedule and was rapidly followed by initial dosing in all trial participants....
16.07.26 - 18:01
Insiderhandel: Aufsichtsrat kauft Aktien von Vivani Medical im Wert von 999999 USD (Insiderkauf)
 
Williams, Gregg - Aufsichtsrat - Tag der Transaktion: 2026-07-15...
16.07.26 - 01:12
Vivani Medical auf Wachstumskonferenz: Implantat-Strategie gewinnt an Dynamik (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
14.07.26 - 22:06
Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026 (GlobeNewswire EN)
 
ALAMEDA, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative, biopharmaceutical company developing novel, miniature, GLP-1 drug implants with once- or twice-yearly administration, today announced that it will present at the Emerging Growth Conference on July 15, 2026....
11.07.26 - 14:12
A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss (CNBC)
 
Vivani Medical is developing an implant of semaglutide, the active ingredient in Novo Nordisk's obesity injection Wegovy and diabetes counterpart Ozempic....
07.07.26 - 16:01
Novo Nordisk-Aktie im Plus: Pharmariese kooperiert mit Vivani Medical bei Semaglutid-Implantat (Finanzen.net)
 
Vivani Medical hat sich einen prominenten Partner für sein Semaglutid-Implantat gesichert, und der Markt reagiert sichtbar....
07.07.26 - 15:42
Vivani Medical In Deal With Novo Nordisk To Evaluate Semaglutide Drug Implant NPM-139 (AFX)
 
BRUSSELS (dpa-AFX) - On Tuesday, Vivani Medical, Inc. (VANI), a biopharmaceutical company focused on ultra long-acting drug implants, announced a new agreement, under which Novo Nordisk B A/S (NVO......
07.07.26 - 13:39
Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management (GlobeNewswire EN)
 
Vivani Medical entered into agreement with Novo Nordisk to evaluate its miniature subdermal semaglutide (GLP-1) implant for weight management...
02.07.26 - 14:06
ClearOne Announces Entry into Merger Agreement with Cortigent, Inc., a Wholly-Owned Subsidiary of Vivani Medical (Business Wire)
 
SALT LAKE CITY--(BUSINESS WIRE)--ClearOne, Inc. (Nasdaq: CLRO) (“ClearOne”) announced today that it has entered into a definitive agreement and plan of merger (the “Agreement”) among its wholly-owned subsidiary (“MergerSub”), Vivani Medical, Inc. (Nasdaq: VANI; “Vivani”), and Cortigent, Inc. (“Cortigent”), a wholly-owned subsidiary of Vivani, pursuant to which Cortigent will become a wholly-owned subsidiary of ClearOne (the “Transaction”) upon consummation. In connection with the Transaction, ClearOne has agreed to file a registration statement on Form S-1 to raise a minimum of $10,000,000 and a maximum of $15,000,000 (the “Financing”) concurrently with the closing of the Transaction (the “Closing”). “I am excited to announce this transaction. In my view, Cortigent's mission, to help patients recover sight and motor function through precision neurostimulation, is compelling given both the technical outlook for their neurostimulation technology and the significant unmet m...
26.06.26 - 13:33
Vivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean Baker (GlobeNewswire EN)
 
ALAMEDA, Calif., June 26, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the appointment of August Moretti to its board of directors. Concurrent with this appointment, the Company announced the retirement of Dr. Dean Baker from the board....
25.06.26 - 13:33
Vivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Management (GlobeNewswire EN)
 
ALAMEDA, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that it has received approval from Bellberry, a human research ethics committee (HREC) in Australia to initiate SLIM-1™, a Phase 1 clinical trial of NPM-139, a semaglutide implant....
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Der Geschmack hängt nicht an unseren Bedürfnissen. Der Mann muß schon sehr gesittet sein, wenn er eine Frau nach Geschmack wählen soll. - Immanuel Kant
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!